AZD1152 (Barasertib)

AZD1152 (Barasertib) is an inhibitor of Aurora Kinases and AURKB used in studies of Cell Cycle Regulation. It is especially relevant in cancer, cell cycle, and cell signaling models, where defined compound exposure can be linked to checkpoint control, mitotic progression, and proliferation timing.

By inhibiting Aurora Kinases and AURKB, AZD1152 (Barasertib) can be used to examine checkpoint control, mitotic progression, and proliferation timing. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving Aurora Kinases and AURKB
• Pathway perturbation studies connected to Cell Cycle Regulation
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, AZD1152 (Barasertib) is appropriate when a defined chemical perturbant is needed to connect Aurora Kinases and AURKB with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.